Leyden Laboratories announced that it has raised €30 million in equity financing from the European Innovation Council (EIC) Fund and Invest-NL to support development of its PanFlu intranasal human monoclonal antibody for the prevention and treatment of influenza as well as additional intranasal candidates. In January 2025, Leyden Labs announced that it had closed a $70 million funding round, and the company announced a €20 million financing deal with the European Investment Bank in June 2025.
Leyden Labs CEO Koenraad Wiedhaup commented, “With PanFlu, we are taking a bold step to stop influenza viruses at the gate. We are proud to welcome these two esteemed European funds, each with the goal of accelerating innovations in Europe that deliver public benefit. Their support for our strategy to develop novel products to protect against respiratory viruses is a wonderful endorsement of our relentless efforts.”
Read the Leyden Labs press release
